Mottiwala Aziz 4

What Happened

• Mottiwala Aziz, Chief Commercial Officer of Tarsus Pharmaceuticals (TARS), had 26,482 Restricted Stock Units (RSUs vest) settle into shares on March 15, 2026. The same 26,482 shares were effectively withheld/converted for tax/settlement purposes in four derivative disposals (4,790; 8,148; 8,020; 5,524), leaving no net new shares delivered to Aziz.
• The filing shows the acquisition as an exercise/conversion of a derivative (code M) and the disposals reported at $0.00 — consistent with net share settlement/tax withholding rather than open-market sales.

Key Details

• Transaction date: March 15, 2026 (Report filed March 17, 2026 — timely).
• Acquired: 26,482 shares issued upon settlement of vested RSUs (footnote F1). Disposed/withheld: 4,790; 8,148; 8,020; 5,524 shares (total withheld = 26,482).
• Prices/values reported: acquisition listed as N/A; disposals reported at $0.00 (reflecting share withholding/conversion, not cash sales).
• Shares owned after transaction: not specified in the provided extract.
• Notable footnotes: RSUs represent contingent rights to one share each (F3); multiple RSU grants from 2022–2025 with standard 25% annual vesting on March 15 of relevant years (F4–F7). F2 notes 497 ESPP shares acquired in 2025 are included in the reporting person’s holdings.
• Filing timeliness: filed two days after the transaction date — appears timely (not late).

Context

• These entries reflect RSU vesting and net share settlement to cover taxes or other withholding obligations (routine administrative transactions). They are not open-market sales and do not necessarily indicate the insider is reducing exposure via market transactions.
• Transaction code M indicates conversion/exercise of a derivative (here, RSUs converting to common shares); the disposals at $0 typically mean shares were withheld rather than sold for cash.